Cargando…

Apixaban enhances endogenous fibrinolysis in patients with atrial fibrillation

AIMS: Approximately 20% of ischaemic stroke patients exhibit spontaneous arterial recanalization, attributable to endogenous fibrinolysis, which strongly relates to improved functional outcome. The impact of oral anticoagulants on endogenous fibrinolysis is unknown. Our aim was to test the hypothesi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spinthakis, Nikolaos, Gue, Ying, Farag, Mohamed, Srinivasan, Manivannan, Wellsted, David, Arachchillage, Deepa R J, Lip, Gregory Y H, Gorog, Diana A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735819/ https://www.ncbi.nlm.nih.gov/pubmed/31505618 http://dx.doi.org/10.1093/europace/euz176

Ejemplares similares

Impaired endogenous fibrinolysis at high shear using a point-of-care test in STEMI is associated with alterations in clot architecture
por: Spinthakis, Nikolaos, et al.
Publicado: (2019)

Precision Treatment in ACS–Role of Assessing Fibrinolysis
por: Gue, Ying X., et al.
Publicado: (2021)

Determinants of Endogenous Fibrinolysis in Whole Blood Under High Shear in Patients With Myocardial Infarction
por: Kanji, Rahim, et al.
Publicado: (2022)

Role, Laboratory Assessment and Clinical Relevance of Fibrin, Factor XIII and Endogenous Fibrinolysis in Arterial and Venous Thrombosis
por: Memtsas, Vassilios P., et al.
Publicado: (2021)

Rationale and design of “Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)” study: A randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome
por: Gue, Ying X., et al.
Publicado: (2019)

Importance of Endogenous Fibrinolysis in Platelet Thrombus Formation
por: Gue, Ying X., et al.
Publicado: (2017)

Use of bioresorbable vascular scaffold: a meta-analysis of patients with coronary artery disease
por: Farag, Mohamed, et al.
Publicado: (2016)

Fibrinolysis in Platelet Thrombi
por: Kanji, Rahim, et al.
Publicado: (2021)

Spontaneous Coronary Artery Dissection: The Phantom Menace
por: Spinthakis, Nikolaos, et al.
Publicado: (2016)

More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy—Current Data and Future Directions
por: Spinthakis, Nikolaos, et al.
Publicado: (2018)

Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation
por: Kirchhof, Paulus, et al.
Publicado: (2018)

Catheter ablation for AF improves global thrombotic profile and enhances fibrinolysis
por: Niespialowska-Steuden, Maria, et al.
Publicado: (2017)

Bivalirudin versus unfractionated heparin: a meta-analysis of patients receiving percutaneous coronary intervention for acute coronary syndromes
por: Farag, Mohamed, et al.
Publicado: (2015)

Safety and Efficacy of Apixaban in the Treatment of Atrial Fibrillation
por: Martin, Andrew, et al.
Publicado: (2012)

Hypertension and atrial fibrillation: Closing a virtuous circle
por: Gue, Ying X., et al.
Publicado: (2021)

Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation
por: Dorian, Paul, et al.
Publicado: (2014)

Short-Term Apixaban for Documented Left Atrial Appendage Thrombus in High-Risk Atrial Fibrillation Patients Undergoing Left Atrial Appendage Occlusion
por: Ding, Wern Yew, et al.
Publicado: (2020)

Intracardiac Hemostasis and Fibrinolysis Parameters in Patients with Atrial Fibrillation
por: Tóth, Noémi Klára, et al.
Publicado: (2017)

Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation
por: Cirincione, Brenda, et al.
Publicado: (2018)

Novel Oral Anticoagulants in Atrial Fibrillation: Update on Apixaban
por: Mezue, Kenechukwu, et al.
Publicado: (2017)

Cost-effectiveness of Apixaban for Stroke Prevention in Patients with Atrial Fibrillation in Algeria
por: Aoudia, Yazid, et al.
Publicado: (2017)

Discontinuation risk comparison among ‘real-world’ newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban
por: Lip, Gregory Y. H., et al.
Publicado: (2018)

Measuring Thrombus Stability at High Shear, Together With Thrombus Formation and Endogenous Fibrinolysis: First Experience Using the Global Thrombosis Test 3 (GTT-3)
por: Kanji, Rahim, et al.
Publicado: (2023)

Early effects of paroxysmal atrial fibrillation on plasma markers of fibrinolysis
por: Negreva, Mariya, et al.
Publicado: (2016)

Meta-analysis Comparing Long-Term Clinical Outcomes of Percutaneous Coronary Intervention versus no Intervention in Patients with Chronic Total Occlusion
por: Ibrahem, Abdalazeem, et al.
Publicado: (2023)

Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban
por: Tepper, Ping G., et al.
Publicado: (2018)

Non-valvular atrial fibrillation: impact of apixaban on patient outcomes
por: Ioannou, Adam, et al.
Publicado: (2017)

Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation
por: Christersson, Christina, et al.
Publicado: (2019)

Use, Persistence, Efficacy, and Safety of Apixaban in Patients with Non-Valvular Atrial Fibrillation in Unselected Patients in Germany. Results of the Prospective Apixaban in Atrial Fibrillation (APAF) Registry
por: Zeymer, Uwe, et al.
Publicado: (2020)

The 2020 ESC Guidelines on the Diagnosis and Management of Atrial Fibrillation
por: Kotalczyk, Agnieszka, et al.
Publicado: (2021)

Effectiveness and Safety of Apixaban in over 3.9 Million People with Atrial Fibrillation: A Systematic Review and Meta-Analysis
por: Buckley, Benjamin J. R., et al.
Publicado: (2022)

Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial
por: Halvorsen, Sigrun, et al.
Publicado: (2014)

Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial
por: Ezekowitz, Michael D, et al.
Publicado: (2018)

Cost-Effectiveness of Apixaban Compared with Warfarin for Stroke Prevention in Atrial Fibrillation
por: Lee, Soyon, et al.
Publicado: (2012)

Laboratory Assessment of the Anticoagulant Activity of Apixaban in Patients With Nonvalvular Atrial Fibrillation
por: Kyriakou, Elias, et al.
Publicado: (2018)

Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation
por: Bahit, M Cecilia, et al.
Publicado: (2017)

Real‐World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
por: Lin, Shin‐Yi, et al.
Publicado: (2019)

Apixaban vs. Warfarin in Atrial Fibrillation Patients With Chronic Kidney Disease
por: Fu, Chung-Ming, et al.
Publicado: (2021)

Rivaroxaban and apixaban in patients with atrial fibrillation; a real-world data
por: ASLAN, Onur, et al.
Publicado: (2022)

Cost-Effectiveness of Apixaban versus Warfarin in Chinese Patients with Non-Valvular Atrial Fibrillation: A Real-Life and Modelling Analyses
por: Li, Xue, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_mnm6hip4st4620925rqt0i4154